ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

 TitleCreatedDownload
application/pdfDrug Safety Update MHRA Feb-2020-PDF.pdf (337KB)13/02/2020Download
 Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of... 
application/pdfDrug Safety Update MHRA Jan-2020-PDF-final.pdf (261KB)29/01/2020Download
 E-cigarettes use or vaping - reporting suspected adverse reactions, including lung injury: Ondansetron - small increased risk of oral clefts following use in the first 12 weeks of pregnancy.... 
application/pdfDrug Safety Update MHRA December 2019 PDF.pdf (201KB)18/12/2019Download
 Domperidone for nausea and vomiting: lack of efficacy in children: reminder of contraindications in adults and adolescents 
application/pdfDrug Safety Update MHRA November 2019-PDF.pdf (252KB)22/11/2019Download
 Yellow fever vaccine: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus:  
application/pdfDrug Safety Update MHRA October 2019 PDF.pdf (336KB)23/10/2019Download
 Ingenol mebutate gel (Picato▼): increased incidence of skin tumours seen in some clinical studies. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation.... 
application/pdfDrug Safety Update MHRA September 2019 PDF.pdf (291KB)23/09/2019Download
  
application/pdfDrug Safety Update MHRA July 2019 PDF.pdf (398KB)18/07/2019Download
 Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease. Tocilizumab (RoActemra): rare risk... 
application/pdfDrug Safety Update MHRA June 2019 PDF.pdf (274KB)20/06/2019Download
 Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome . GLP-1 receptor agonists: reports of diabetic ketoacidosis when... 
application/pdfDrug Safety Update MHRA May 2019 .pdf (512KB)22/05/2019Download
 Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions, Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism... 
application/pdfDrug Safety Update MHRA April 2019 PDF final.pdf (304KB)25/04/2019Download
 Yellow, fever, stamaril, valproate, belimumab, benlysta, lyrica, pregabalin, gabapentin, elvitegravir 
application/pdfDrug Safety Update MHRA March 2019 PDF-final.pdf (388KB)25/03/2019Download
 Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. Onivyde (irinotecan, liposomal... 
application/pdfDrug safety Update MHRA February 2019.pdf (219KB)18/02/2019Download
 Carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Carbimazole: increased risk of Pancreatitis. SGLT2 inhibitors: reports of Fournier's gangrene. 
Page: [1] [2] [3] [4] [5] [6]
[ Next » ]